The CEOs of Johnson & Johnson (JNJ), Merck (MRK), and Bristol Myers Squibb (BMY) are set to appear in front of the Senate health committee to defend how they charge for drugs in the United States, Noah Weiland and Rebecca Robbins of The New York Times report. The three executives are expected to clash with the health committee’s chairman, Senator Bernie Sanders of Vermont, who plans to focus on hearing why drug prices are higher in the U.S. than in other wealthy countries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson accused of mismanaging employees’ drug benefits, WSJ says
- Senate Health, Education, Labor & Pensions Committee holds a hearing
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary